Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation

Why it matters

Almost everyone builds up mutated blood-stem-cell clones with age, but in some people they expand quickly and lead to blood cancer, while in others they stay small. Finding the genes that make some people resilient points to ways to slow this age-related process in everyone. This study traces one protective variant all the way from population genetics to a mechanism in stem cells. Studying people who are naturally protected has found drug targets before; for example, people born with low levels of the protein PCSK9 helped lead to cholesterol-lowering drugs. This study applies the same logic to the aging blood system.

What they did

The researchers searched for inherited variants linked to protection from clonal hematopoiesis and myeloid blood cancers. They identified a non-coding regulatory variant, rs17834140-T, modelled its effects, and mapped which RNAs the protein MSI2 binds in human blood stem cells. They then tested how MSI2 levels affected the growth of stem cells carrying ASXL1 mutations and how the variant related to clone growth over time.

What they found

The variant rs17834140-T protected against clonal hematopoiesis and myeloid cancers by selectively lowering the RNA-binding protein MSI2 in blood stem cells. Mapping MSI2's targets revealed an RNA network that keeps human blood stem cells going and influences clonal hematopoiesis risk. Carriers of the variant had slower clone expansion, and the level of MSI2 in stem cells changed how dominant ASXL1-mutant clones became. The authors suggest that blocking MSI2 or its targets could be a rational way to prevent blood cancer.

Limits

The protective effect is linked to one variant in one gene and mainly to myeloid blood cancers. The abstract does not test an MSI2-blocking drug in people, and lowering MSI2 might affect normal blood-cell production. The clone-growth analyses come from population data, which can be affected by other factors. Carrying or not carrying the variant is not something a person can change, so the practical value lies in the biology it reveals, not in personal testing. Any preventive drug based on it would still need to be developed and tested for safety.

Key terms

Clonal hematopoiesis

Expansion of blood cells descended from one mutated stem cell, common with age.

Hematopoietic stem cell (HSC)

The bone-marrow stem cell that produces all blood cells.

Non-coding variant

An inherited DNA difference outside a protein-coding gene that changes how much of the protein is made.

RNA-binding protein

A protein that controls which messenger RNAs are used, kept or destroyed.

Myeloid malignancy

Cancers of the myeloid blood-cell line, such as acute myeloid leukaemia.

ASXL1

A gene often mutated in clonal hematopoiesis and myeloid cancers.